Input Form
Complete the sections below. The panel updates live with the agents approved for this diagnosis.
Patient profile
Demographics and baseline characteristics
Relevant for ustekinumab, some biologics
Disease characteristics
Current disease burden and distribution
Comorbidities & safety screening
Select all that apply — these directly affect agent choice
✓
Psoriatic arthritis
Favors IL-17 / IL-23 agents
✓
Inflammatory bowel disease
Critical — affects IL-17 eligibility
✓
Cardiovascular disease
Favors IL-23 inhibitors
✓
Allergic asthma
Favors dupilumab (if AD)
✓
Recurrent serious infections
Caution with all systemic agents
✓
Demyelinating disease
Contraindicates TNF inhibitors
✓
Diabetes
Consider monitoring requirements
✓
Obesity (BMI >30)
Affects ustekinumab efficacy
✓
Pregnancy / planning pregnancy
Significantly affects agent choice
✓
Prior or active malignancy
Caution with some agents
✓
Hepatitis B (active or prior)
Antiviral prophylaxis required
✓
TB exposure / latent TB
Must be treated before TNF inhibitors
✓
Thrombosis history (DVT / PE)
Black box warning for systemic JAK and TYK2/JAK inhibitors
✓
Renal impairment
Dose adjustment may be required
✓
Hepatic impairment
Excludes topical PDE4 inhibitors at Child-Pugh B or C
✓
Immunocompromised
Affects topical JAK inhibitor eligibility
✓
Thrombocytopenia
Excludes abrocitinib
✓
Current or past smoking
Raises cardiac and malignancy risk with systemic JAK inhibitors
Pregnancy status
Note: Certolizumab (Cimzia) is the preferred TNF inhibitor in pregnancy — does not cross placenta. For AD, dupilumab has the most reassuring registry data.
Treatment history
Prior and current treatments
Add each systemic agent tried, with the reason it was stopped
Practical factors
Access, preference, and adherence considerations
Oral options exist for some conditions (JAK inhibitors, TYK2 inhibitor)
Applicable agents
Updates live as you complete the form
Complete the form above and the approved agents for this diagnosis will appear here as you make selections.
Complete the form above to generate a personalized recommendation with contraindication alerts.
Not a substitute for clinical judgment or institutional prescribing guidelines.